Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype
Muni Hu(Shanghai Jiao Tong University), Haoyan Chen(Shanghai Jiao Tong University), Baoqin Xuan(Shanghai Jiao Tong University), Jie Hong, Jinmei Ding(Shanghai Jiao Tong University), Xiaoqiang Zhu(Shanghai Jiao Tong University), Lingxi Li(Shanghai Institute of Hematology), Xiuying Xiao(Fudan University Shanghai Cancer Center), Yanru Ma(Shanghai Jiao Tong University), Lijun Ning(Shanghai Jiao Tong University), Xiaowen Huang(Renji Hospital), Huimin Chen(Renji Hospital), Hua Li(Shanghai Jiao Tong University), Zhenyu Wang(Henan Provincial People's Hospital), Ying Zhao(Shanghai Jiao Tong University), Jiantao Li(Guangdong Ocean University), Youwei Zhang(Case Western Reserve University), Yi Jiang(Fujian Medical University), Ye Hu(Ministry of Education of the People's Republic of China), Tianying Tong(Shanghai Jiao Tong University), Jing‐Yuan Fang(Shanghai Jiao Tong University), Yue Zhang(Beijing University of Chinese Medicine), Yilu Zhou(Shanghai Jiao Tong University)
Cited by 10
Related Papers
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
Roles of Chk1 in cell biology and cancer therapy
|International Journal of Cancer|2013|456
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|427
Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts
|Nature Communications|2023|231